Targets › NGLY1
1 program from 1 company in 1 trial: 1 Phase 3; Metabolic and endocrine; next expected readout Mar 2027.
Protein N-glycosidase that mediates deglycosylation of N-linked glycoproteins by cleaving the beta-aspartyl-glucosamine (GlcNAc) of the glycan and the amide side chain of asparagine (Asn), converting Asn to aspartate (Asp). Prefers proteins containing high-mannose over those bearing complex type oligosaccharides. (UniProt, Q96IV0)
Open in Phaseline: the race on NGLY1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Grace Science | GS-100 Gene replacement therapy for NGLY1 deficiency delivered via intracerebroventricular admini | NGLY1 | Phase 3 | NGLY1 Deficiency | Mar 2027 |
NGLY1 Deficiency (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.